Modality
ADC
MOA
CDK2i
Target
AuroraA
Pathway
Innate Imm
Alzheimer's
Development Pipeline
Preclinical
~Jun 2014
→ ~Sep 2015
Phase 1
~Dec 2015
→ ~Mar 2017
Phase 2
Jun 2017
→ Jul 2028
Phase 2Current
NCT08360707
203 pts·Alzheimer's
2017-06→2026-03·Completed
NCT08890874
60 pts·Alzheimer's
2025-11→2028-07·Completed
263 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-162w agoPh3 Readout· Alzheimer's
2028-07-272.3y awayPh3 Readout· Alzheimer's
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2/3
Complet…
P2/3
Complet…
Catalysts
Ph3 Readout
2026-03-16 · 2w ago
Alzheimer's
Ph3 Readout
2028-07-27 · 2.3y away
Alzheimer's
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08360707 | Phase 2/3 | Alzheimer's | Completed | 203 | NT-proBNP |
| NCT08890874 | Phase 2/3 | Alzheimer's | Completed | 60 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D |